- $338.28m
- $133.14m
CEO Robert Lisicki To Take Medical Leave - SEC Filing
Zura Bio Ltd expected to post a loss of 19 cents a share - Earnings Preview
Brief: Zura Bio Appoints Eric Hyllengren As CFO Effective July 7, 2025
Brief: Zura Bio Launches Global Phase 2 Tibushield Study To Evaluate Tibulizumab In Adults With Hidradenitis Suppurativa
Zura Bio Ltd reports results for the quarter ended March 31 - Earnings Summary
Zura Bio Ltd expected to post a loss of 15 cents a share - Earnings Preview
Zura Bio Ltd reports results for the quarter ended December 31 - Earnings Summary
Brief: Zura Bio Reports Full Year 2024 Financial Results And Recent Corporate Updates
Zura Bio Ltd expected to post a loss of 16 cents a share - Earnings Preview
Zura Bio Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Zura Bio Announces Expiration And Results Of Exchange Offer
Zura Bio Ltd expected to post a loss of 15 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gold miners, Hasbro, VinFast
U.S. STOCKS ON THE MOVE-Zura Bio, MicroStrategy, Gold miners
Zura Bio rises on positive early-stage results for immune disease drug
Brief: Zura Bio Ltd Tibulizumab (ZB-106) Was Well Tolerated And Neutralized Il-17A And Baff In A Phase 1 Study In Patients With Sjogren's Syndrome
Brief: Zura Bio Ltd Files For Resale Of Up To 41.6 Mln Class A Ordinary Shares
Zura Bio Ltd expected to post a loss of 23 cents a share - Earnings Preview
Brief: Zura Bio Announces Oversubscribed $112.5 Million Private Placement